🔍

JBCHEPHARM - J B Chemicals &

📊 NSE: JBCHEPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:30

📢 Recent Corporate Announcements

JB Chemicals & Pharmaceuticals: Resignation of GM Corporate Strategy Ms. Sushree Mishra

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 13 Mar 2026, 07:10 PM

JB Chemicals & Pharmaceuticals Limited has announced the resignation of Ms. Sushree Mishra, who served as the General Manager - Corporate Strategy, Communication and In-licensing. Her departure was effective from the close of business hours on March 13, 2026, following a resignation letter submitted on February 9, 2026. This change is classified as a change in Senior Management Personnel under SEBI regulations. The company has not yet announced a successor for this strategic role.

Ms. Sushree Mishra resigned as General Manager - Corporate Strategy, Communication and In-licensing.
The resignation became effective as of the close of business hours on March 13, 2026.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The resignation letter was submitted on February 9, 2026, allowing for a standard transition period.

💡 This is a routine management change and does not necessitate any immediate action from investors. Monitor for future appointments to the strategy and in-licensing team to ensure continuity in business development.

JB Chemicals Executive VP Jason D’souza Resigns Effective March 6, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 11 Mar 2026, 06:08 PM

JB Chemicals & Pharmaceuticals Limited has announced the resignation of Mr. Jason D’souza from his role as Executive Vice President. The resignation became effective at the close of business hours on March 6, 2026. The company filed the disclosure on March 11, 2026, following a request from BSE for a fresh announcement regarding the cessation of Senior Management Personnel. The company acknowledged a delay in the initial intimation to the stock exchanges due to inadvertence.

Mr. Jason D’souza resigned as Executive Vice President effective March 6, 2026.
The official disclosure to stock exchanges was made on March 11, 2026.
The company cited inadvertence for the delay in reporting the management change.
The transition is categorized as a change in Senior Management Personnel under SEBI Regulation 30.

💡 Investors should treat this as a routine management transition and monitor if there are further exits in the senior leadership team. No immediate portfolio action is required based on this announcement.

JB Chemicals Announces Resignation of Three Senior Management Personnel Including India Head

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 10 Mar 2026, 06:02 PM

JB Chemicals & Pharmaceuticals has announced the departure of three key senior executives in March 2026. Mr. Kunal Khanna (President – Operations) and Mr. Dilip Singh Rathore (President – India Business) both stepped down effective March 5, 2026. Additionally, Mr. Jason D’souza (Executive Vice President) resigned effective March 6, 2026. The simultaneous exit of leaders overseeing operations and the critical India business segment is a significant leadership transition for the company.

Mr. Kunal Khanna resigned as President – Operations effective March 5, 2026
Mr. Dilip Singh Rathore resigned as President (India Business) effective March 5, 2026
Mr. Jason D’souza resigned as Executive Vice President effective March 6, 2026
All three senior management personnel ceased their roles within a 24-hour window

💡 Investors should monitor the company's upcoming announcements regarding succession planning and ensure that the transition in the India Business segment does not disrupt domestic growth momentum.

JB Chemicals Seeks Approval to Appoint Aman Mehta as MD and Three New Directors

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 20 Feb 2026, 10:40 PM

JB Chemicals & Pharmaceuticals has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Aman Mehta as Managing Director for a three-year term effective January 21, 2026. Notably, the proposed MD appointment is without any remuneration. The company is also seeking approval for the appointment of three Non-Executive Non-Independent Directors: Mr. Amal Kelshikar, Mr. Hasmukh Patel, and Mr. Sudhir Menon. Shareholders can cast their votes via e-voting between February 22 and March 23, 2026, with results expected by March 25, 2026.

Proposed appointment of Mr. Aman Mehta as Managing Director for a 3-year term starting January 21, 2026.
The Managing Director position for Mr. Aman Mehta is proposed with zero remuneration.
Three additional Non-Executive Non-Independent Directors are proposed for appointment to the Board.
Remote e-voting period is set from February 22, 2026, to March 23, 2026.
Final results of the postal ballot will be announced on or before March 25, 2026.

💡 Investors should monitor the outcome of the voting to ensure continuity in leadership and observe if these changes signal any shift in corporate strategy. The zero-remuneration clause for the MD is a specific point of interest regarding the company's cost management or promoter alignment.

JB Chemicals Allots 31,160 Equity Shares Under ESOP Scheme 2021

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Feb 2026, 05:10 PM

JB Chemicals & Pharmaceuticals Limited has allotted 31,160 equity shares of Re. 1 each to an employee following the exercise of stock options. The company realized approximately Rs. 1.87 crore from this exercise under the JBCPL Employee Stock Option Scheme, 2021. This allotment has marginally increased the total paid-up equity capital to 16,05,58,706 shares. Such actions are routine for companies using stock options as part of their compensation strategy.

Allotment of 31,160 fully paid-up equity shares of Re. 1 each on February 19, 2026
Total amount realized from the exercise of options stands at Rs. 1,86,96,000
Paid-up equity capital increased from 16,05,27,546 to 16,05,58,706 shares
The allotment was made under the JBCPL Employee Stock Option Scheme, 2021

💡 This is a routine administrative update with negligible equity dilution. No specific action is required as it does not impact the company's fundamental value.

JB Chemicals Announces Resignation of VP-Legal Himanshu Ranvah

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 07 Feb 2026, 02:06 PM

JB Chemicals & Pharmaceuticals Limited has announced that Mr. Himanshu Ranvah, Vice President - Legal, has resigned from his position effective February 6, 2026. The resignation was tendered on January 23, 2026, as part of a planned transition. To ensure continuity, his responsibilities are being handed over to Mr. Vishal Chavan. This change is considered a routine senior management movement and is not expected to disrupt the company's strategic direction.

Mr. Himanshu Ranvah ceased to be the Vice President - Legal effective closing of business hours on February 6, 2026.
The resignation letter was submitted on January 23, 2026, citing personal reasons after a successful tenure.
Work responsibilities are being transitioned to Mr. Vishal Chavan to ensure a smooth handover process.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 This is a routine senior management exit and does not warrant any change in investment thesis. Investors should continue to focus on the company's quarterly performance and growth in the domestic and international markets.

JB Chemicals Announces Resignation of Presidents for Operations and India Business

🔵 WATCH ⭐ 6/10

MANAGEMENT 📅 05 Feb 2026, 09:55 PM

JB Chemicals & Pharmaceuticals Limited has announced the simultaneous resignation of two key senior management personnel. Mr. Kunal Khanna, President of Operations, and Mr. Dilip Singh Rathore, President of the India Business, will step down effective March 5, 2026. The departure of the India Business head is particularly significant as this segment is a primary revenue driver for the company. Investors should watch for the announcement of successors to ensure leadership continuity.

Mr. Kunal Khanna, President – Operations, resigned effective March 5, 2026.
Mr. Dilip Singh Rathore, President – India Business, resigned effective March 5, 2026.
Both resignations were tendered on February 5, 2026, providing a one-month notice period.
The India Business segment is a core growth pillar for the company's domestic pharmaceutical operations.

💡 Monitor for the appointment of new leadership to lead the India Business and Operations divisions to ensure a smooth transition. No immediate action is required, but leadership stability in the domestic market is critical for long-term performance.

JB Chemicals Sets February 11, 2026, as Record Date for Interim Dividend

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 05 Feb 2026, 07:14 PM

JB Chemicals & Pharmaceuticals Limited has officially designated February 11, 2026, as the record date to determine shareholder eligibility for an interim dividend for FY 2025-2026. This announcement follows the company's board meeting processes and complies with SEBI's Listing Obligations and Disclosure Requirements. The record date is crucial for investors as it defines who will receive the cash payout. Shareholders must hold the company's equity shares in their demat accounts by the close of business on this date to qualify.

Record date fixed for Wednesday, February 11, 2026
Purpose is to ascertain eligibility for Interim Dividend for FY 2025-2026
Announcement made in compliance with Regulation 42 of SEBI LODR Regulations, 2015
The notification was issued to the National Stock Exchange on February 5, 2026

💡 Investors seeking to capture the interim dividend should ensure they purchase shares at least one trading day prior to the ex-dividend date. Current shareholders should maintain their holdings through the record date of February 11, 2026, to ensure eligibility.

JB Chemicals Declares Rs 12.70 Interim Dividend and Appoints Kaushal Solanki as CFO

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 05 Feb 2026, 07:12 PM

JB Chemicals & Pharmaceuticals has declared an interim dividend of Rs 12.70 per equity share for the financial year 2025-26, representing a 1270% payout on its Re 1 face value. The dividend is scheduled to be credited to eligible shareholders on or after February 25, 2026. In a significant leadership update, the company also appointed Mr. Kaushal Solanki as the Chief Financial Officer. Mr. Solanki joins with over 30 years of experience, having previously held senior leadership roles at Torrent Pharmaceuticals.

Declared an interim dividend of Rs 12.70 per equity share (1270% of face value).
Dividend payment to be credited to shareholders starting February 25, 2026.
Appointed Mr. Kaushal Solanki as CFO and Key Managerial Personnel effective February 5, 2026.
New CFO brings 30+ years of experience, including a long-term tenure at Torrent Pharmaceuticals.
The board meeting concluded within 30 minutes, reflecting efficient decision-making on these key items.

💡 Investors should monitor the record date to ensure eligibility for the Rs 12.70 dividend. The appointment of a seasoned CFO from a major peer like Torrent Pharma is a positive signal for the company's financial leadership and governance.

JB Chemicals CFO Narayan Saraf Resigns Effective January 30, 2026

🔵 WATCH ⭐ 6/10

MANAGEMENT 📅 05 Feb 2026, 06:55 PM

JB Chemicals & Pharmaceuticals Limited has announced that Mr. Narayan Saraf has stepped down from his role as Chief Financial Officer (CFO) and Key Managerial Personnel. The resignation became effective at the close of business hours on January 30, 2026. Mr. Saraf cited personal reasons and the pursuit of other professional opportunities as the primary reasons for his departure. The company had previously notified the exchanges of this transition on January 29, 2026, and has now submitted the formal resignation letter.

Mr. Narayan Saraf ceased to be the CFO and Key Managerial Personnel effective January 30, 2026.
The resignation letter was formally dated January 28, 2026, and submitted to the board.
Departure is attributed to personal reasons and the pursuit of other professional opportunities.
The company confirmed there are no other material reasons for the resignation beyond those stated.

💡 Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure a smooth transition in financial leadership. While management changes can create temporary uncertainty, the impact will depend on the profile and experience of the successor.

JB Chemicals Shifts Registered Office from Maharashtra to Gujarat

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 11:08 PM

JB Chemicals & Pharmaceuticals Limited has officially shifted its registered office from the State of Maharashtra to Ahmedabad, Gujarat. The move was approved by the Ministry of Corporate Affairs via a certificate dated February 4, 2026, following a special resolution by the company. This administrative change shifts the company's jurisdiction from ROC Mumbai to ROC Ahmedabad. The company's corporate office will continue to maintain a presence in Mumbai.

Registered office shifted from Maharashtra to Ahmedabad, Gujarat effective February 4, 2026.
Approval granted by the Ministry of Corporate Affairs following a Regional Director order dated January 6, 2026.
New registered address is 302, Iscon Mall, Star India Bazar Building, Ahmedabad - 380015.
Clause II of the Memorandum of Association has been amended to reflect the change in state jurisdiction.

💡 This is a routine administrative matter with no impact on the company's business operations or financial performance. No action is required from investors.

JB Chemicals Allots 92,490 Equity Shares Under ESOP Scheme

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Jan 2026, 06:30 PM

JB Chemicals & Pharmaceuticals Limited has allotted 92,490 equity shares of Re. 1 each to employees following the exercise of stock options under the JBCPL Employee Stock Option Scheme, 2021. This exercise has resulted in a capital realization of approximately Rs. 5.55 crore for the company. As a result, the total paid-up equity share capital has increased from 16,04,35,056 to 16,05,27,546 shares. The dilution caused by this allotment is marginal and is part of the company's employee retention and incentive strategy.

Allotment of 92,490 fully paid-up equity shares of Re. 1 each on January 30, 2026.
Total amount realized from the exercise of options stands at Rs. 5,54,94,000.
Total issued and paid-up capital increased to 16,05,27,546 equity shares.
The shares were issued under the JBCPL Employee Stock Option Scheme, 2021.

💡 This is a routine administrative update with negligible impact on the stock's valuation or earnings per share. No specific action is required from investors based on this announcement.

JB Chemicals CFO Narayan Saraf Resigns; Effective January 30, 2026

🔵 WATCH ⭐ 6/10

MANAGEMENT 📅 29 Jan 2026, 03:42 PM

JB Chemicals & Pharmaceuticals Limited has announced the resignation of its Chief Financial Officer, Mr. Narayan Saraf. The resignation was tendered on January 28, 2026, and is set to be effective from the close of business on January 30, 2026. The company cited personal reasons and the pursuit of other professional opportunities as the cause for his departure. Notably, the transition period appears extremely short, with the announcement coming just one day before the effective date.

Mr. Narayan Saraf resigned as CFO and Key Managerial Personnel on January 28, 2026.
The resignation is effective from the closing of business hours on January 30, 2026.
Reasons for resignation are cited as personal and to pursue other professional opportunities.
The company confirmed there are no other material reasons for the sudden departure.
The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should monitor the company's next steps regarding the appointment of a successor to ensure leadership continuity. The abruptness of the CFO's exit warrants a cautious watch on the upcoming quarterly financial reporting process.

JB Pharma Q3 FY26 Net Profit Jumps 22% to ₹198 Cr; Gross Margins Expand to 69.1%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 21 Jan 2026, 09:43 PM

JB Chemicals & Pharmaceuticals (JB Pharma) delivered a solid Q3 FY26 performance with revenue rising 11% YoY to ₹1,065 crore and net profit surging 22% to ₹198 crore. Profitability improved significantly as gross margins expanded 200 bps to 69.1% and EBITDA margins reached 28.7%. The domestic formulation business grew 10%, continuing to outperform the Indian Pharma Market (IPM), while international formulations grew 20%. Management reiterated its FY26 operating margin guidance of 27-29% and noted the Torrent merger is on track for Q4 closure.

Revenue grew 11% YoY to ₹1,065 crore, driven by domestic and international formulation growth.
Net profit increased 22% to ₹198 crore, supported by a 200 bps expansion in gross margins to 69.1%.
Domestic formulations revenue stood at ₹620 crore, representing a 10% YoY growth and outperforming the market.
International formulations grew 20% to ₹306 crore, led by strong performance in Russia, South Africa, and the US.
Management maintained operating margin guidance of 27-29% for FY26 despite a flat CDMO performance due to a high base.

💡 The company remains a strong play on domestic market outperformance and margin expansion through product mix optimization. Investors should monitor the Torrent merger closure in Q4 for potential long-term synergies.

Torrent Pharma Completes 46.39% Stake Acquisition in JB Chemicals; Gains Control

🟢 POSITIVE ⭐ 10/10

M&A 📅 21 Jan 2026, 09:40 PM

Torrent Pharmaceuticals has finalized the acquisition of a 46.39% stake (7,44,81,519 shares) in JB Chemicals from Tau Investment Holdings. With this completion, Torrent Pharma has officially assumed control of the company, while the former promoter, Tau Investment, has exited its entire holding. The reclassification of Tau Investment from 'promoter' to 'public' category is effective from January 21, 2026. This move follows the share purchase agreement dated June 29, 2025, and a subsequent open offer.

Acquisition of 7,44,81,519 shares (46.39% stake) by Torrent Pharmaceuticals completed on Jan 21, 2026
Tau Investment Holdings has ceased to be a promoter and now holds zero equity shares in the company
Torrent Pharma has officially acquired control of JB Chemicals & Pharmaceuticals Limited
Reclassification of the outgoing promoter to the 'public' category is now effective under SEBI regulations

💡 The entry of Torrent Pharma as the new promoter is a significant milestone that could drive long-term value through operational synergies. Shareholders should stay invested and watch for upcoming strategic announcements from the new management.

View All JBCHEPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Overall revenue grew 8% YoY to INR 1,085 Cr in Q2 FY26. Domestic formulations grew 9% to INR 644 Cr. The CDMO segment reported robust growth of 20% to INR 113 Cr, while International Formulations grew 2% to INR 306 Cr. For the first nine months of fiscal 2025, revenue grew 13% to INR 2,969 Cr.

Geographic Revenue Split

The revenue mix for H1 FY26 was 61% Domestic and 39% International, compared to a 59%/41% split in H1 FY25. International markets include Russia (strong growth), USA, UK, South Africa, Australia, Canada, Africa, South-east Asia, and the Middle East.

Profitability Margins

Gross margins improved by 200 bps to 68.2% in Q2 FY26 from 66.2% YoY, driven by a favorable product mix and price growth. Net profit grew 19% YoY to INR 208 Cr. Operating margins are expected to remain healthy at 26-28% over the medium term.

EBITDA Margin

Operating EBITDA margin (excluding non-cash ESOP) was 29.4% in Q2 FY26, up 100 bps from 28.4% YoY. Operating EBITDA reached INR 319 Cr, a 12% increase, reflecting strong emphasis on cost discipline and execution excellence.

Capital Expenditure

The company plans an annual organic maintenance capex of ~INR 100 Cr. Net capex addition for H1 FY26 was INR 46 Cr compared to INR 49 Cr in H1 FY25. A significant cash consideration of $116 million (approx. INR 970 Cr) is due to Novartis by December 31, 2026, for a Trademark License Agreement.

Credit Rating & Borrowing

The company maintains a healthy financial risk profile with an adjusted gearing of 0.01 times as of March 31, 2025. Gross debt was reduced to INR 7 Cr as of September 30, 2025, from INR 14 Cr in March 2025. Interest coverage ratios are exceptionally high at over 80 times.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) are the primary raw materials. While specific cost percentages per API are not disclosed, the company noted anticipated increases in API costs, leading to strategic inventory building.

Import Sources

Not specifically disclosed in the documents, though the company operates manufacturing units in Ankleshwar and exports to regulated markets like the US and Europe.

Capacity Expansion

Planned organic capex of ~INR 100 Cr annually is focused on maintenance and efficiency. The company is also integrating the acquired ophthalmology portfolio, which is expected to trigger a perpetual license in December 2026.

Raw Material Costs

Raw material costs are managed through cost-optimization efforts and strategic inventory management. Gross margins of 68.2% suggest raw material and direct production costs represent approximately 31.8% of revenue.

Manufacturing Efficiency

Efficiency is driven by a focus on 'progressive' portfolios (65-70% of presence) and chronic therapies. The company is a top 5 global CDMO for lozenges, benefiting from high-standard global approvals.

📈 Strategic Growth

Expected Growth Rate

11-13%

Growth Strategy

Growth will be driven by outperforming the Indian Pharma Market (IPM) with a target of 12-14% domestic growth, ramping up the CDMO business (which grew 20% in Q2 FY26), and leveraging past acquisitions like Sanzyme, Azmarda, and Razel. The company also expects a significant margin boost from the ophthalmology portfolio starting in 2027.

Products & Services

The company sells pharmaceutical formulations (tablets, capsules, injectables), lozenges, and Active Pharmaceutical Ingredients (APIs). Key therapeutic areas include chronic, progressive, and ophthalmology portfolios.

Brand Portfolio

Razel (Cardiovascular), Azmarda (Heart failure), Sanzyme (Probiotics), and various brands acquired from Dr. Reddy’s and Novartis.

New Products/Services

New product launches and the ramp-up of the recently acquired ophthalmology portfolio are expected to be major contributors. The ophthalmology segment is projected to provide a significant gross margin improvement from CY 2027 onwards.

Market Expansion

Focusing on the 'progressive' portfolio (65-70% of current business) and expanding the CDMO lozenges business globally. Russia remains a key growth market in the international segment.

Market Share & Ranking

Ranked 20th in chronic therapies as of Dec 2024 (up from 25th). It is the fastest-growing company among the top 25 in the Indian Pharmaceutical Market (IPM).

Strategic Alliances

Trademark License Agreement with Novartis Switzerland for the ophthalmology portfolio; strategic acquisitions from Sanzyme Pvt Ltd and Dr. Reddy’s Laboratories.

🌍 External Factors

Industry Trends

The Indian Pharma Market (IPM) is growing at 8%, while JB Pharma is growing at 12%, indicating a shift toward high-growth chronic and progressive therapies. The CDMO sector for specialized forms like lozenges is expanding globally.

Competitive Landscape

Faces intense competition from other large Indian pharma players and global generic manufacturers. Competitors include the top 25 companies in the IPM.

Competitive Moat

Moat is built on a top 5 global position in lozenges CDMO, strong brand equity in chronic therapies (Razel, Azmarda), and a high-margin 'progressive' portfolio. These are sustainable due to high regulatory barriers and established physician trust.

Macro Economic Sensitivity

Sensitive to domestic healthcare regulatory changes and pricing controls. Domestic growth of 12% vs IPM growth of 8% shows high resilience to general market trends.

Consumer Behavior

Shift toward chronic disease management and preventive healthcare is driving demand for the company's cardiovascular and probiotic portfolios.

Geopolitical Risks

Exposure to the Russian market, which showed strong growth in Q2 FY26, carries inherent geopolitical risk. Trade barriers in regulated markets (US/Europe) could also impact the CDMO business.

⚖️ Regulatory & Governance

Industry Regulations

Subject to stringent manufacturing standards from global regulators (US FDA, Europe) for its CDMO business and domestic pricing controls for formulations.

Legal Contingencies

The company is managing a non-cash ESOP charge with a remaining balance of approximately INR 47 Cr. No specific court cases or values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

The potential acquisition of a stake in JBCPL by Torrent Pharmaceuticals is a key monitorable factor that could lead to management changes and impact strategic direction.